Valuation: Pelthos Therapeutics Inc.

Market Cap 101M 87.35M 81.77M 74.61M 140M 9.61B 143M 959M 376M 4.81B 378M 370M 16.05B P/E 2026 *
-2.48x
P/E 2027 * -16x
Enterprise Value 101M 87.35M 81.77M 74.61M 140M 9.61B 143M 959M 376M 4.81B 378M 370M 16.05B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 0.83x
Free-Float
46.22%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week+7.23%
Current month-0.10%
1 month+9.07%
3 months+6.63%
6 months+29.78%
Current year-7.65%
1 week 26.82
Extreme 26.825
29.52
1 month 24.6
Extreme 24.6
29.52
Current year 18.19
Extreme 18.19
30.99
1 year 16.5
Extreme 16.5
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-558 0.0161%
02/07/26 Sell

Director

-786 0.0226%
02/07/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+7.23%+50.68% - 101M
-1.37%+8.90%+91.28%+130.00% 1,098B
-0.77%+1.91%+49.46%+49.44% 631B
+0.85%+2.58%+25.90%+64.34% 438B
-1.13%+3.62%+49.72%+38.22% 368B
-0.74%+1.09%+33.81%+38.95% 298B
-1.22%+2.99%+8.44%+6.11% 251B
-0.70%+6.23%+45.32%+57.82% 226B
+0.34%+1.62%-4.91%-50.77% 209B
+2.04%+0.38%+12.70%+69.71% 165B
Average -0.22%+1,494.33%+36.24%+44.87% 368.44B
Weighted average by Cap. -0.51%+1,331.46%+50.10%+66.03%

Financials

2026 *2027 *
Net sales 63.92M 55.39M 51.85M 47.31M 89.03M 6.1B 90.53M 608M 238M 3.05B 240M 235M 10.18B 121M 105M 98.31M 89.7M 169M 11.56B 172M 1.15B 452M 5.79B 455M 445M 19.3B
Net income -41.39M -35.87M -33.58M -30.64M -57.65M -3.95B -58.62M -394M -154M -1.98B -155M -152M -6.59B -6.74M -5.84M -5.47M -4.99M -9.39M -643M -9.54M -64.1M -25.11M -322M -25.3M -24.75M -1.07B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
11/08/26 US$28.63 -1.28% 37,820
10/08/26 US$29.00 +2.26% 21,444
07/08/26 US$28.36 -3.70% 42,086
06/08/26 US$29.45 +3.19% 75,781
05/08/26 US$28.54 +6.89% 59,723
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
29.00USD
Average target price
57.71USD
Spread / Average Target
+99.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock